Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Pfizer 4Q

Pfizer completed its acquisition of Wyeth in the quarter. U.S. revenues were $7.4 billion in the quarter (+42%).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer 4Q

4Q Revenues: $16.5 billion (+34%)

4Q Earnings: $767 million (+188%)

FY Revenues: $50.0 billion (+4%)

FY Earnings: $8.6 billion (+7%)

Comments: Pfizer completed its acquisition of Wyeth in the quarter. U.S. revenues were $7.4 billion in the quarter (+42%). International revenues were $9.1 billion (+28%), reflecting 21% operational growth and a 7% favorable impact of foreign exchange. 4Q09 results were favorably impacted by $3.3 billion, or 27%, due to the addition of Wyeth products, $419 million, or 3%, for Pfizer products, and $469 million, or 4%, due to foreign exchange. Biopharmaceutical revenues in the quarter were 14.6 billion (+30%). For the year, revenues were favorably impacted by approximately $3.3 billion (+7%) with the addition of Wyeth products, $247 million (+1%) due to Pfizer products, and unfavorably impacted by $1.8 billion, (-4%), due to foreign exchange. U.S. revenues were $21.7 billion (+7%) and International revenues were $28.3 billion (+1%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters